KY 455

Drug Profile

KY 455

Latest Information Update: 06 Mar 2008

Price : $50

At a glance

  • Originator Kyoto Pharmaceutical Industries
  • Class Alkanes; Antihyperlipidaemics; Indoles; Small molecules
  • Mechanism of Action Antioxidants; Sterol O-acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 06 Mar 2008 Discontinued - Preclinical for Hyperlipidaemia in Japan (unspecified route)
  • 30 May 2000 A preclinical study has been added to the Hyperlipidaemia pharmacodynamics section
  • 16 Jan 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top